Please login to the form below

Not currently logged in
Email:
Password:

Cervarix given EU marketing authorisation

GSK's cervical cancer drug Cervarix has been granted a marketing authorisation for all 27 EU member states, as well as Iceland, Norway and Liechtenstein, putting it head to head with Merck's drug Gardasil

GlaxoSmithKline's (GSK's) cervical cancer drug Cervarix has been granted a marketing authorisation for all 27 EU member states, as well as Iceland, Norway and Liechtenstein, putting it head to head with Merck's vaccine Gardasil.

It is reported that GSK will begin marketing Cervarix in Europe in the next few weeks, but the price of the drug is unknown. Gardasil is priced at GBP 80.50 for a 0.5 ml shot, with treatment involving three doses.

The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in July 2007 based on a review of data from clinical trials which involved almost 30,000 females and which demonstrated good efficacy and immunogenicity data.

Cervarix has been shown to be 100 per cent effective in preventing infection with HPV strains 16 and 18, which together cause about 70 per cent of cervical cancer cases.

Europe is the latest region after Kenya, Australia and the United Arab Emirates to approve marketing of Cervarix.

Cervarix became available in Kenya at the beginning of September 2007 after the country's Pharmacy and Poison's Board approved it for marketing.

GSK is awaiting approval from the US Food and Drug Administration (FDA) approval after submitting its application to the FDA in April 2007. Cervarix will not be on the US market until some time in 2008 after it was refused a fast track six month review. The drug is currently undergoing a 10-month standard review.

Cervarix is formulated with an adjuvant system called AS04, which is designed to enhance the immune response and increase the duration of protection against cancer-causing virus types.

Analysts have projected peak annual sales of USD 2.5bn for Gardasil and USD 1.5bn in peak annual sales for Cervarix.

2nd September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics